Atlas FDA

VASCADE VASCULAR CLOSURE SYSTEM (VCS)

FDA premarket approval P120016/S021 · decided 2018-03-30

Approval details

PMA number
P120016
Supplement
S021
Supplement type
Normal 180 Day Track
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Trade name
VASCADE VASCULAR CLOSURE SYSTEM (VCS)
Generic name
Device, hemostasis, vascular
Applicant
Cardiva Medical, Inc.
Date received
2016-11-04
Decision date
2018-03-30
Days to decision
511 days
Decision code
APPR
Product code
MGB
Advisory committee
Cardiovascular
Expedited review
No
Location
Santa Clara, CA
Statement
Approval to expand the indication of the VASCADE VCS to include femoral venous access site closure.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
CATALYST II AND III (K130124)Cardiva Medical, Inc.2013-03-14
CARDIVA CATALYST III SYSTEM WITH PROTAMINE SULFATE (K082930)Cardiva Medical, Inc.2009-02-13
BOOMERANG CATALYST/BOOMERANG CATALYST II SYSTEM (K072297)Cardiva Medical, Inc.2007-09-12
BOOMERANG WIRE /BOOMERANG PLUS WIRE SYSTEM, MODEL# B PLUS WIRE 58L (K070485)Cardiva Medical, Inc.2007-03-22
BOOMERANG CLOSUREWIRE VASCULAR CLOSURE SYSTEM (K051817)Cardiva Medical, Inc.2006-12-06
BOOMERANG WIRE (K061075)Cardiva Medical, Inc.2006-09-01
VASOSTASIS VASCULAR CLOSURE SYSTEM (K041486)Cardiva Medical, Inc.2004-10-22